Connect
← Return to Anyone on Pluvicto (Lu 177), a new drug for prostate cancer?
Discussion
Anyone on Pluvicto (Lu 177), a new drug for prostate cancer?
Prostate Cancer | Last Active: Feb 27 9:46am | Replies (171)Comment receiving replies
Thanks @leebeth for your report on Lu177. I have been told I am not ready yet for the treatment. As of today I am holding my own having had Eligard for 3.5 years, 44 radiation treatments, zolodronic acid infusions every 3 months, bicalutimide and enzalutimide, Radium223 treatments and docetaxel. Not sure how long I will hold steady. PSA is starting to rise but other indicators are holding steady. Bone scans are especially positive. I appreciate all the information on Lu177. It is very helpful. My decision time is now down the road a bit.
Replies to "Thanks @leebeth for your report on Lu177. I have been told I am not ready yet..."
Darolutimide has been approved for metastatic castrate sensitive PC google it
On August 5, 2022, the Food and Drug Administration approved darolutamide (Nubeqa, Bayer HealthCare Pharmaceuticals Inc.) tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Connect
That’s wonderful that you are holding your own for so long! You are very fortunate! My husband has been on docetaxel for 6 cycles, and carbazitaxel/carboplatin for 8 cycles. Degarelix and now Orgovyx, simply for convenience.
6 fractions of SBRT to prostate, and palliative fractions to hip, spine, shoulder.
Now on Xtandi to help with PSMA expression to help the Lu-177 do it’s best work.
By the time you are ready, we will know so much more!